Sareums flagship Chk1 inhibitor shows serious lung cancer potential in mouse models

Sareum’s flagship Chk1 inhibitor shows serious lung cancer potential in mouse models

05:40 EDT 2 Apr 2019 | Proactive Investors

After 50 days, eight out of ten mice achieved a complete response, which means there was no detectable sign of cancer anymore

More From BioPortfolio on "Sareum’s flagship Chk1 inhibitor shows serious lung cancer potential in mouse models"